Related Experiment Videos
[Expression of hepatitis C virus genome]
T Nishihara1, K Mizuno, T Shikata
1First Department of Pathology, Nihon University School of Medicine.
Nihon Rinsho. Japanese Journal of Clinical Medicine
|February 1, 1993
Summary
Hepatitis C virus (HCV) proteins were expressed for diagnostic use. Antibodies against envelope glycoproteins E1 and E2/NS1 were detected in patients, indicating distinct immune responses to these HCV components.
Area of Science:
- * Molecular biology and virology, focusing on Hepatitis C Virus (HCV) genome expression and protein analysis.
- * Recombinant protein expression in prokaryotic (E. coli) and eukaryotic (insect) systems.
- * Immunological assays, specifically Enzyme-Linked Immunosorbent Assay (ELISA), for antibody detection.
Context:
- * Hepatitis C Virus (HCV) infection remains a significant global health concern, necessitating improved diagnostic tools.
- * Understanding the immune response to specific HCV proteins is crucial for developing effective diagnostics and potential therapies.
- * Previous diagnostic strategies may not fully capture the breadth of immune responses in infected individuals.
Purpose:
- * To express and analyze complementary DNAs (cDNAs) from the HCV genome.
- * To evaluate the utility of synthesized HCV proteins (C8-2, core, E1, E2/NS1) as diagnostic probes.
- * To investigate the immune response against HCV envelope glycoproteins (E1 and E2/NS1) in patients with chronic liver disease.
Summary:
- * Complementary DNAs (cDNAs) encoding Hepatitis C Virus (HCV) proteins, including C8-2 (part of NS5) and core protein (JCC), were successfully synthesized in E. coli, with core protein showing diagnostic potential.
- * Predicted envelope glycoproteins E1 and E2/NS1 were produced in insect cells, glycosylated, and secreted when fused with a rabies virus G protein signal sequence.
- * An Enzyme-Linked Immunosorbent Assay (ELISA) revealed anti-E2/NS1 antibodies in over 88% of patients with non-A, non-B chronic liver diseases, compared to anti-E1 antibodies in 20%, suggesting differential immune recognition.
Impact:
- * Demonstrates the potential of recombinant HCV core protein as a diagnostic marker for HCV infection.
- * Highlights the significant immune response directed against the E2/NS1 glycoprotein in patients with chronic liver disease.
- * Provides evidence for distinct immunological profiles against different HCV envelope glycoproteins, informing future diagnostic and therapeutic strategies.